MALAT1 and glioblastoma: Overexpression of MALAT1 was initially identified in non-small cell lung cancer (NSCLC) and has been correlated with tumor initiation, progression, distant metastasis, autophagy, drug resistance, and poor outcome in several types of tumor [52], such as glioblastoma [55], breast cancer [50], colorectal cancer [21], acute myeloid leukemia [56].